Takeshi Imaoka

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura et al. · The Lancet Diabetes & Endocrinology · 2022 · 191 citations

Diabetes Management, Diabetes, Pharmacology +7

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

Takashi Kadowaki, Rina Chin, Akichika Ozeki et al. · The Lancet Diabetes & Endocrinology · 2022 · 115 citations

Diabetes Management, Diabetes, Pharmacology +6

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in <scp>J</scp> apanese patients with type 2 diabetes: a 26‐week randomized phase <scp>III</scp> study

Jun‐ichiro Miyagawa, Masato Odawara, Toshinari Takamura et al. · Diabetes Obesity and Metabolism · 2015 · 93 citations · Full text

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

Nobuya Inagaki, Yoshihito Atsumi, Tomonori Oura et al. · Clinical Therapeutics · 2012 · 84 citations

Diabetes Management, Insulin Management, Diabetes +8

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in <scp>A</scp>sian men

Osamu Yokoyama, Masaki Yoshida, Sae Chul Kim et al. · International Journal of Urology · 2012 · 84 citations